Prostate cancer is, today, the most frequent cancer and the second most frequent cause of death for cancer in USA. The watchful waiting approach, that has been traditionally proposed by urological communities in Northern Europe, is still matter of debate. The following review will consider the clinical studies published in Literature and will discuss the most controversial issues.
ZietmanA.L., CocaJ.J., DallowK.C.. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome.Int J Radiat Oncol Biol Phys1995; 32: 287–92.
6.
SchultheissT.E., LeeW.R.. Late GI and GU complication in the treatment of prostate cancer.Int J Radiat Oncol Biol Phys1997; 37: 3–11.
7.
RagdeH., GradoG.L., NadirB.S.. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.Arch Esp Urol2001, 54: 739–47.
ChaussyC., ThuroffS., VallancienG.. HIFU for the treatment of localised prostate cancer: Efficacy results of Multicenter study.J Urol2001; 165: 388.
10.
European Association of Urology, Guidelines, 2002.
11.
ChodakG.W., ThisedR.A., GlennS.. Results of conservative management of clinically localized prostate cancer.NEJM1994; 3300: 242–7.
12.
IversenP., MadsenP.O., CorleD.K.. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate twenty-three years of follow up of a prospective randomized study.Scand J Urol Nephrol1995; 172(suppl.): S65–72.
13.
HolmbergL., Bill AxelsonA., HelgesenF.. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.NEJM2002; 347: 781–9.
14.
WalshP.C.: Surgery and reduction of mortality from prostate cancer.NEJM2004; 347: 839–40.
15.
CarterHB, WalshPC, LandisP, EpsteinJL. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.J Urol2002; 167: 1231–4.
16.
EpsteinJL, WalshPC, CarmichaelM. Pathologic and clinical finding to predict tumor extent of non palpable (stage T1c) prostate cancer.JAMA1994; 271: 368–71.
